Errata - English

In Analysis: Change
Result = (R_U/R_S) × (C_S/C_U) × ^▲(M_r1/M_r2) ×_{▲ (USP 1-Aug-2019)} 100
to:
Result = (R_U/R_S) × (C_S/C_U) × 100
AND
Delete
^▲M_r1 = molecular weight of tiagabine hydrochloride, 412.00
M_r2 = molecular weight of tiagabine hydrochloride monohydrate, 430.02_{▲ (USP 1-Aug-2019)}

In System suitability stock solution B: Change
2 mg/mL each of campesterol, stigmasterol, and USP β-Sitosterol RS and 0.37 mg/mL of stigmastanol
to:
0.37 mg/mL of stigmastanol and 2 mg/mL each of campesterol, stigmasterol, and USP β-Sitosterol RS in chloroform

In System suitability stock solution B: Change
2 mg/mL each of campesterol, stigmasterol, and USP β-Sitosterol RS, and 0.37 mg/mL of stigmastanol
to:
0.37 mg/mL of stigmastanol and 2 mg/mL each of campesterol, stigmasterol, and USP β-Sitosterol RS in chloroform

In B: Change
It meets the requirements in the test Viscosity—Capillary Methods <911>, Viscosity—Rotational Methods <912>, and Viscosity—Rolling Ball Method <913>.
to:
It meets the requirements in the test Viscosity—Capillary Methods <911>, Viscosity—Rotational Methods <912>, or Viscosity—Rolling Ball Method <913>.

In Test 1/Tolerances and Test 3/Tolerances: Change
[(C₁₇H₁₉NO₃)₂ · H₂SO₄ · 5H₂O)]
to:
[(C₁₇H₁₉NO₃)₂ · H₂SO₄ · 5H₂O]

In USP Sumatriptan Succinate Related Impurities RS: Change
Mixture of sumatriptan succinate, [3-[2-(methylamino) ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide maleate salt, sumatriptan succinate related compound C, [3-[2-(dimethylamino-N-oxide)ethyl]-1H-indol- 5-yl]-N-methylmethanesulfonamide, and [3-[2-(aminoethyl)]-1H-indol-5-yl]-N-methyl methanesulfonamide.
to:
Mixture of sumatriptan succinate, [3-[2-(methylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide, sumatriptan succinate related compound C, [3-[2-(dimethylamino-N-oxide)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide, and [3-[2-(aminoethyl)]-1H-indol-5-yl]-N-methyl methanesulfonamide.

In Peptone diluent: Change
Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing
to:
Dispense into sterile containers as needed for preparing samples.
Trace mineral solution: Prepare a solution containing

In USP Clomiphene Related Compound A RS: Change
(E,Z)-2-[4-(1,2-Diphenylethyl)phenoxy]-N,N-diethylethanamine hydrochloride.
to:
(E,Z)-2-[4-(1,2-Diphenylvinyl)phenoxy]-N,N-diethylethanamine hydrochloride.
Also known as (E,Z)-2-[4-(1,2-Diphenylethenyl)phenoxy]-N,N-diethylethanamine hydrochloride.

Change
Each mL of 0.1 N perchloric acid is equivalent to 7.953 mg of C₄H₁₀N₂ · 2HCl.
to:
Each mL of 0.1 N perchloric acid is equivalent to 9.207 mg of C₄H₁₀N₂ · H₃PO₄.

In Peptone diluent: Change
Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing
to:
Dispense into sterile containers as needed for preparing samples.
Trace mineral solution: Prepare a solution containing

In Analysis: Change
r_C = peak response of ceftiofur from the Sample solution (mg/mL)
r_A = sum of the responses of all peaks that elute after ceftiofur from the Sample solution (mg/mL)
to:
r_C = peak response of ceftiofur from the Sample solution
r_A = sum of the responses of all peaks that elute after ceftiofur from the Sample solution

In the second equation in Analysis: Change
Result = (R_L − P_B)/(P_A − P_B)
to:
Result = (R_L − P_B)/(P_A − P_B) × 100

In USP Telmisartan Related Compound A RS: Change
1,7’-Dimethyl-2’-propyl-1H,3’H-2,5’-bibenzo[d]imidazole.
C₁₉H₂₀N₄ 304.39
to:
1,7’-Dimethyl-2’-propyl-1H,3’H-2,5’-bibenzo[d]imidazole monohydrate.
C₁₉H₂₀N₄ ∙ H₂O 322.41

In Absorptivity: Change
The absorptivity of the Sample solution at 445 nm is NLT 95.0% and NMT 103.0% that of the Standard solution.
to:
The absorptivity, calculated on the dried basis, of the Sample solution at 445 nm is NLT 95.0% and NMT 103.0% that of the Standard solution.

In USP Sumatriptan Succinate Related Impurities RS: Change
Mixture of sumatriptan succinate, [3-[2-(methylamino) ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide maleate salt, sumatriptan succinate related compound C, [3-[2-(dimethylamino-N-oxide)ethyl]-1H-indol- 5-yl]-N-methylmethanesulfonamide, and [3-[2-(aminoethyl)]-1H-indol-5-yl]-N-methyl methanesulfonamide.
to:
Mixture of sumatriptan succinate, [3-[2-(methylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide, sumatriptan succinate related compound C, [3-[2-(dimethylamino-N-oxide)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide, and [3-[2-(aminoethyl)]-1H-indol-5-yl]-N-methyl methanesulfonamide.

In Aflatoxin standard solution: Change
ε = molecular absorptivity
to:
ε = molar absorptivity
AND
in paragraph 2 of Aflatoxin standard solution: Change
transfer an accurate volume of each aflatoxin standard stock solution
to:
transfer an accurate volume of each aflatoxin stock solution

In USP Cetirizine Related Compound A RS: Change
2-(2-{4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl}ethoxy)acetic acid, ethyl ester dihydrochloride.
C₂₃H₂₉ClN₂O₃ · 2HCl 489.86
to:
(RS)-2-[2-[4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic acid ethyl ester oxalate.
C₂₃H₂₉ClN₂O₃ · C₂H₂O₄ 506.98

Change
C_S = concentration of USP Diphenhydramine Hydrochloride RS and USP Ibuprofen RS in the Standard solution (mg/mL)
to:
C_S = concentration of USP Diphenhydramine Hydrochloride RS or USP Ibuprofen RS in the Standard solution (mg/mL)

In Analysis: Change
r_C = peak response of ceftiofur from the Sample solution (mg/mL)
r_A = sum of the responses of all peaks that elute after ceftiofur from the Sample solution (mg/mL)
to:
r_C = peak response of ceftiofur from the Sample solution
r_A = sum of the responses of all peaks that elute after ceftiofur from the Sample solution

In Mobile phase: Change
^▲Acetonitrile, methanol, and acetic acid (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL of triethylamine._{▲ (USP 1-May-2019)}
to:
Acetonitrile and methanol (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL of triethylamine.

In Analysis: Change
Result = [(V_S − V_B) x N_A x F] x 100
to:
Result = [(V_S − V_B) x N_A x F x 100]/W
AND
Change
F = equivalency factor, 84.01 mg/mL
to:
F = equivalency factor, 84.01 mg/mEq
W = sample weight (mg)